Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00722137
First received: July 23, 2008
Last updated: November 8, 2014
Last verified: November 2014
  Purpose

This is a randomized, open-label, multicentre, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.


Condition Intervention Phase
Mantle Cell Lymphoma
Drug: Rituximab 375 mg/m^2
Drug: Cyclophosphamide 750 mg/m^2
Drug: Doxorubicin 50 mg/m^2
Drug: VELCADE 1.3 mg/m^2
Drug: Prednisone 100 mg/m^2
Drug: Vincristine 1.4 mg/m^2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant

Resource links provided by NLM:


Further study details as provided by Millennium Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.


Secondary Outcome Measures:
  • Time to Progression (TTP) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee.

  • Duration of Response [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH).

  • Time to Next Anti-lymphoma Treatment (TTNT) [ Time Frame: : Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive.

  • Treatment-free Interval (TFI) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive.

  • Overall Response Rate (ORR) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

  • Overall Complete Response (CR + CRu) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). ). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

  • Overall Survival (OS) [ Time Frame: Median duration of follow-up of 40 months ] [ Designated as safety issue: No ]
    OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.

  • 18-Month Survival [ Time Frame: Up to month 18 from the time of randomization ] [ Designated as safety issue: No ]
    18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate).

  • Number of Participants Experiencing an Adverse Event (AE) [ Time Frame: Up to Week 28 ] [ Designated as safety issue: Yes ]
    An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug.


Enrollment: 487
Study Start Date: May 2008
Estimated Study Completion Date: January 2015
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: R-CHOP
Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
Drug: Rituximab 375 mg/m^2
Intravenous rituximab 375 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles.
Drug: Cyclophosphamide 750 mg/m^2
Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles
Drug: Doxorubicin 50 mg/m^2
Intravenous doxorubicin 50 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles
Drug: Prednisone 100 mg/m^2
Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
Drug: Vincristine 1.4 mg/m^2
Intravenous vincristine 1.4 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
Experimental: VcR-CAP
Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
Drug: Rituximab 375 mg/m^2
Intravenous rituximab 375 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles.
Drug: Cyclophosphamide 750 mg/m^2
Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles
Drug: Doxorubicin 50 mg/m^2
Intravenous doxorubicin 50 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles
Drug: VELCADE 1.3 mg/m^2
Intravenous VELCADE 1.3 mg/m^2 on Days 1,4,8, and 11of a 21 day (3 week) cycle for 6 cycles
Drug: Prednisone 100 mg/m^2
Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place)

    • Diagnosis of MCL (Stage II, III or IV) as evidenced by lymph node histology and either expression of cyclin D1 (in association with CD20 and CD5) or evidence of t(11;14) translocation, such as by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR). Patients with a diagnosis of Stage I MCL will not be permitted to enter study.

  • Paraffin embedded biopsy tissue block (preferably of lymph node origin) must be sent to the central laboratory for confirmation of MCL diagnosis prior to randomization. In China, a paraffin embedded lymph node biopsy tissue block must be sent for central confirmation of sample adequacy, prior to randomization

    • At least 1 measurable site of disease
    • No prior therapies for MCL
    • Not eligible for bone marrow transplantation as assessed by the treating physician (e.g., age or the presence of co-morbid conditions that may have a negative impact on the tolerability to transplantation).
    • Eastern Cooperative Oncology Group ECOG status ≤2 (Attachment 1)
    • Absolute neutrophil count (ANC) ≥1500 cells/µL,
    • Platelets ≥100,000 cells/µL or ≥75,000 cells/µL if thrombocytopenia is considered by the investigator to be secondary to MCL (e.g., due to bone marrow infiltration or sequestration from splenomegaly).
    • Alanine transaminase ≤3 x upper limit of normal (ULN)
    • Aspartate transaminase ≤3 x ULN
    • Total bilirubin ≤1.5 x ULN,
    • Calculated creatinine clearance ≥20 mL/min. (Attachment 2)
    • Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) and have a negative serum βHCG or urine pregnancy test at screening. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
    • Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study.
    • All patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
    • In order to participate in the pharmacogenomics component of this study, patients (or their legally acceptable representative) must have signed the informed consent form for pharmacogenomics research indicating willingness to participate in the pharmacogenomics component of the study. Acquisition of tumor sample collections is required for all patients (where available); all other sample collections are optional

Exclusion Criteria:

-Excl criteria on EUCTR is as follows: Potential patients who meet any of the following criteria will be excluded from participating in the study:

  • Prior treatment with VELCADE
  • Prior antineoplastic (including unconjugated therapeutic antibodies), experimental or radiation therapy, radioimmunoconjugates or toxin immunoconjugates for the treatment of MCL. In the event that a patient has received doxorubicin for the treatment of any condition, other than MCL, the maximum dose and exposure received prior to entry into this study should not exceed 150 mg/m2.

    - short course (maximum of 10 days, not exceeding 100 mg/day) prednisone or equivalent steroids are allowed to treat symptoms in patients with advanced disease who enter the screening phase and are waiting to be randomized.

  • Major surgery (at the discretion of the treating physician and in consultation with the sponsor's medical monitor) within 2 weeks before randomization
  • Peripheral neuropathy or neuropathic pain of Grade 2 or worse (as per the investigators assessment)
  • Diagnosed or treated for a malignancy other than MCL within 1 year of randomization, or who were previously diagnosed with a malignancy other than MCL and have any radiographic or biochemical marker evidence of malignancy. Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded.
  • Active systemic infection requiring treatment and patients with known diagnosis of HIV or active hepatitis B (carriers of hepatitis B are permitted to enter study)
  • History of allergic reaction attributable to compounds containing boron, mannitol, or hydroxybenzoates
  • Known anaphylaxis or immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate
  • Female or male patients of child-bearing potential who will not use adequate contraception during the course of the study.
  • Serious medical (e.g., pericardial disease, cardiac failure [New York Heart Association; NYHA Class III or IV, Attachment 12 or left ventricular ejection fraction; LVEF <50%], active peptic ulceration, uncontrolled diabetes mellitus, or acute diffuse infiltrative pulmonary disease), or psychiatric illness likely to interfere with participation in this clinical study
  • Concurrent treatment with another investigational agent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00722137

  Show 150 Study Locations
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Medical Monitor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

No publications provided

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00722137     History of Changes
Other Study ID Numbers: 26866138-LYM-3002, 26866138-LYM-3002CTIL, U1111-1150-2776, 2007-005669-37
Study First Received: July 23, 2008
Results First Received: November 8, 2014
Last Updated: November 8, 2014
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Japan: Ministry of Health, Labor and Welfare
Korea: Food and Drug Administration

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Bortezomib
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine
Alkylating Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors

ClinicalTrials.gov processed this record on November 25, 2014